68% Fewer Denials, $1.4M Saved: Ending BCBSM Authorization Gaps at a Michigan Infusion Network

Michigan infusion claim denials tied to BCBSM authorization gaps are quietly draining revenue from practices across the state. When prior authorization requirements shift without warning, high-cost biologics get denied, and the clock starts ticking on money your practice may never collect. 

At Infusion Billing Services, we recently worked with a Michigan infusion network that had accepted these denials as a cost of doing business. Their BCBSM authorization write-offs kept appearing across different treatment scenarios, and no single fix seemed to address them all.

Michigan infusion claim denials often look like isolated billing errors. In reality, they share one root cause. This case study explains five ways the same BCBSM authorization gap surfaced across their network. It also shows how fixing one single front-end check reduced Michigan infusion claim denials by 68% and recovered $1.4 million.

 

Client Snapshot

Our client was a Michigan infusion network operating across multiple treatment sites. The network included several prescribing physicians, nurse practitioners, and covering providers. Monthly claim volume exceeded 750 submissions across commercial payers, with BCBSM representing the largest share of revenue at risk. The network had also recently absorbed patients from an acquired infusion practice. These patients brought treatment histories that lived in legacy systems not yet fully connected to the group’s billing platform. The network wanted to understand why Michigan infusion claim denials kept returning despite staff training.

We reviewed twelve months of denial data before starting this engagement. BCBSM authorization gaps accounted for $1.4 million in cumulative write-offs. Every one of these Michigan infusion claim denials traced back to the same front-end weakness. No single check existed to verify authorization coverage across the entire course of treatment.

 

Denial Reason 1: Authorization Expired Mid-Treatment Cycle

Infusion treatments normally take place in cycles that span days, weeks, or months. An existing authorization may approve only certain numbers of treatments or a limited treatment period. In the event an authorization expires during a cycle, then any further treatment is not covered despite the medical necessity.

Problem:

• Authorization covered an initial dose count rather than the full treatment course
• Later sessions in the same cycle were billed without valid authorization
• Staff assumed the original approval extended through the entire prescribed duration

Fix:

• Built a front-end check that flags authorizations set to expire before the scheduled completion date
• Created an alert system requiring reauthorization before the expiration window closes
• Verified authorization validity at each session, not just at the first infusion

This gap was the largest single driver of Michigan infusion claim denials in the network’s data. This pattern was the most common source of Michigan infusion claim denials.

 

Denial Reason 2: Payer Requirement Updates Not Tracked

BCBSM maintains its PA drug list and medical policy changes all through the year. Drugs that were previously exempt from prior authorization may no longer be so. Similarly, site of care limitation was restricted to in-patient hospital sites, but now has expanded elsewhere.

Problem:

• Staff used a static authorization checklist that became outdated between updates
• New BCBSM requirements were discovered only after claims denied
• No process existed to monitor payer policy changes proactively

Fix:

• Established a monitoring process for BCBSM medical drug lists and provider bulletins
• Updated the front-end authorization check whenever payer requirements changed
• Cross-referenced scheduled infusions against the current authorization list before each appointment

This fix prevented Michigan infusion claim denials from arising simply because the practice was working from stale information. It also gave staff a repeatable way to avoid Michigan infusion claim denials.

 

Denial Reason 3: Coding Mismatch Between Authorization and Claim

When a prior authorization has been done for one code, say a CPT or a HCPCS code, it doesn’t mean it will necessarily cover another slight variation in the code at the time of billing. This situation is especially true in cases of infusion claims since all codes should match the prior authorization.

Problem:

• Authorization specified a particular J-code or CPT code that differed from the billed code
• Administration code hierarchy errors created discrepancies between approval and claim
• Units billed exceeded or did not match authorized units

Fix:

• Built a pre-submission check comparing authorization codes to claim codes
• Verified that J-codes, CPT codes, and units matched the approved authorization before claim release
• Flagged any discrepancy for resolution before the claim left the system

This fix eliminated Michigan infusion claim denials that occurred despite having a valid authorization on file. It also reduced Michigan infusion claim denials from coding mismatches.

 

Denial Reason 4: Site-of-Care Restrictions Not Verified at Scheduling

The BCBSM site-of-care policy mandates certain infusible medications must be delivered at particular facilities, with hospital outpatient facilities not being an option unless there is medical need for it. In case of scheduling without verification of such limitations, the claim gets denied irrespective of its medical appropriateness.

Problem:

• Patients were scheduled for hospital outpatient infusion without confirming site-of-care approval
• The authorization covered the drug but not the proposed location of care
• Staff did not recognize that site-of-care verification was a separate step from drug authorization

Fix:

• Added site-of-care verification to the front-end authorization check
• Confirmed the scheduled location matched the authorized site before appointment confirmation
• Redirected patients to approved alternate sites when restrictions applied

This fix prevented Michigan infusion claim denials that had nothing to do with clinical care quality. Site-of-care checks are now a standard defense against Michigan infusion claim denials.

 

Denial Reason 5: Covering Provider Authorizations Not Linked to the Group

Temporary covering providers sometimes administer infusions during scheduling gaps. When the covering provider’s authorization records are not linked to the primary practice’s system, the infusion may proceed without valid authorization under the group’s contract.

Problem:

• Covering provider authorizations existed in separate, unconnected records
• Staff did not verify that covering visits were covered under the group’s authorization
• Claims submitted under the covering provider’s NPI denied for missing authorization

Fix:

• Linked covering provider authorization data to the group’s front-end check
• Verified covering provider authorizations before confirming any scheduled infusion
• Ensured all authorization records flowed into the same verification system

This fix reduced Michigan infusion claim denials tied to covering provider gaps. It also stopped Michigan infusion claim denials from hiding in unlinked records.

 

How One Front-End Check Recovered $1.4M

Every one of these five reasons traced back to the same root problem. Authorization verification was being checked too narrowly at the point of scheduling. Drug approvals were checked separately from site-of-care approvals. Initial authorizations were treated as covering entire treatment courses. Payer updates were discovered after claims were denied rather than before appointments were scheduled.

Building one comprehensive front-end check, spanning the full treatment course, every code, every site, and every provider, solved all five at once. This was not five separate fixes bundled together into one project. It was a single front-end authorization check applied consistently across every BCBSM scenario. The network now reviews every scheduled infusion against the same checklist to prevent Michigan infusion claim denials. For Michigan infusion providers, this meant Michigan infusion claim denials dropped sharply without adding staff or increasing appeal volume.

 

Financial Recovery Results

The table below shows the value recovered by scenario across the review period. Every dollar here traced back to the same BCBSM authorization front-end correction that reduced Michigan infusion claim denials.

Denial Scenario	Revenue Recovered	Outcome
Mid-treatment authorization expiration	$520,000	Recovered
Payer requirement updates not tracked	$310,000	Recovered
Coding mismatch between authorization and claim	$240,000	Recovered
Site-of-care restrictions not verified	$190,000	Recovered
Covering provider authorization gap	$140,000	Recovered
Total revenue recovered	$1,400,000	Combined outcome

 

Metric	Before Fix	After Fix
BCBSM authorization denial rate	9%	3%
Claims correctly authorized at scheduling	74%	96%
Average time to catch an authorization gap	28 days	2 days
Overall reduction in this denial pattern	0%	68%

These results confirm that a single front-end authorization check resolved several BCBSM denial patterns at once. Fragmented, provider-specific checks had been the actual root cause all along. That single correction explains why Michigan infusion claim denials fell so sharply.

 

Key Takeaways

These lessons help Michigan infusion practices prevent recurring Michigan infusion claim denials.

• Verify that authorizations cover the full treatment course, not just the initial doses
• Monitor BCBSM medical drug lists and provider bulletins for requirement updates
• Match authorization codes to claim codes before submission
• Confirm site-of-care compliance as a separate step from drug authorization
• Link covering provider authorizations to the group’s verification system

 

Conclusion:

Michigan infusion claim denials tied to BCBSM authorization gaps almost always trace back to one narrow front-end check. Mid-treatment expirations, payer updates, coding mismatches, site-of-care restrictions, and covering provider gaps all expose this same weakness. As this case shows, building one comprehensive authorization check recovered $1.4 million and reduced Michigan infusion claim denials by 68%. A single, well-designed front-end fix outperformed five separate, disconnected efforts.

If your Michigan infusion practice faces recurring BCBSM authorization write-offs, we can help. Infusion Billing Services can build one comprehensive check to stop Michigan infusion claim denials before they start. A single fix, applied consistently, often solves more than it first appears to. Contact Infusion Billing Services today for a BCBSM authorization gap assessment. Start fixing Michigan infusion claim denials with one front-end authorization check.